UY28933A1 - Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos - Google Patents

Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos

Info

Publication number
UY28933A1
UY28933A1 UY28933A UY28933A UY28933A1 UY 28933 A1 UY28933 A1 UY 28933A1 UY 28933 A UY28933 A UY 28933A UY 28933 A UY28933 A UY 28933A UY 28933 A1 UY28933 A1 UY 28933A1
Authority
UY
Uruguay
Prior art keywords
beta
combinations
adrenergic agonists
antimuscarinic agents
include antimuscarinic
Prior art date
Application number
UY28933A
Other languages
English (en)
Inventor
Jordi Gras Escardo
Jesus Lenas Calvo
Hamish Ryder
Pio Orviz Diaz
Original Assignee
Almirall Prodesfarma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34956036&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY28933(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Prodesfarma Sa filed Critical Almirall Prodesfarma Sa
Publication of UY28933A1 publication Critical patent/UY28933A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Combinaciones de ciertos agentes antimuscarínicos con agonistas beta-adrenérgicos, procedimientos para su producción y su uso en el tratamiento de trastornos respiratorios.
UY28933A 2004-05-31 2005-05-31 Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos UY28933A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200401312A ES2257152B1 (es) 2004-05-31 2004-05-31 Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.

Publications (1)

Publication Number Publication Date
UY28933A1 true UY28933A1 (es) 2005-08-31

Family

ID=34956036

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28933A UY28933A1 (es) 2004-05-31 2005-05-31 Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos

Country Status (46)

Country Link
US (41) US20050267078A1 (es)
EP (14) EP2210613A1 (es)
JP (8) JP5032984B2 (es)
KR (3) KR20130027586A (es)
CN (8) CN101018566A (es)
AR (1) AR049066A1 (es)
AT (3) ATE424847T1 (es)
AU (3) AU2005247108B2 (es)
BE (1) BE1016608A5 (es)
BR (6) BRPI0511669A (es)
CA (3) CA2569077C (es)
CH (1) CH696962A5 (es)
CL (1) CL2011000607A1 (es)
CY (7) CY1108885T1 (es)
DE (3) DE602005022497D1 (es)
DK (5) DK1763369T3 (es)
EC (6) ECSP067038A (es)
ES (7) ES2257152B1 (es)
FR (1) FR2870744B1 (es)
GB (1) GB2419819B (es)
GR (1) GR1006045B (es)
HK (4) HK1090306A1 (es)
HR (4) HRP20090107T3 (es)
HU (2) HUP0600139A3 (es)
IL (3) IL179689A (es)
IT (1) ITMI20051021A1 (es)
LT (1) LTC1763368I2 (es)
LU (1) LU91214B1 (es)
MC (1) MC200083A1 (es)
ME (4) ME01680B (es)
MX (3) MXPA06013847A (es)
MY (1) MY142095A (es)
NL (2) NL1029151C2 (es)
NO (7) NO20065477L (es)
NZ (3) NZ551667A (es)
PE (3) PE20081649A1 (es)
PL (6) PL1763369T3 (es)
PT (4) PT2292267E (es)
RS (4) RS53529B1 (es)
RU (4) RU2385721C2 (es)
SI (5) SI21784A (es)
TW (1) TWI404530B (es)
UA (6) UA89182C2 (es)
UY (1) UY28933A1 (es)
WO (3) WO2005115462A1 (es)
ZA (6) ZA200600261B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100471016B1 (ko) * 1996-08-07 2005-07-12 스미또모 가가꾸 가부시키가이샤 살충성에어로졸조성물및이를제조하기위한살충조성물
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
AU2004262901B2 (en) * 2003-07-29 2010-05-13 Boehringer Ingelheim International Gmbh Combination of an anticholinergic and a steroid and its use to treat respiratory disorders by inhalation
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
PL1905451T3 (pl) * 2004-05-31 2010-05-31 Almirall Sa Kombinacje obejmujące środki przeciwmuskarynowe i kortykosteroidy
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
WO2006085689A1 (ja) * 2005-02-10 2006-08-17 Oncolys Biopharma, Inc. テロメライシン併用抗癌剤
EP1971369B1 (en) * 2005-12-21 2009-08-19 MEDA Pharma GmbH & Co. KG Combination of r,r-glycopyrrolate, rolipram and budesonide for the treatment of inflammatory diseases
WO2007096782A2 (en) * 2006-02-22 2007-08-30 Valorisation Recherche Hscm, Limited Partnership Compositions for disorders associated wtth metachromatic cell activation
US8007790B2 (en) * 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
TWI436761B (zh) * 2006-06-19 2014-05-11 Otsuka Pharma Co Ltd 使用噻唑衍生物之方法
PL2359826T3 (pl) 2006-07-05 2014-04-30 Astrazeneca Ab Połączenie inhibitora reduktazy HMG-CoA rosuwastatyny z inhibitorem fosfodiesterazy 4, takim jak roflumilast, N-tlenek roflumilastu, do leczenia chorób zapalnych płuc
CA2657639A1 (en) 2006-07-19 2008-01-24 Astrazeneca Ab Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
PT2120936E (pt) * 2007-02-21 2011-09-06 Almirall Sa Métodos inovadores
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
EP2080523A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Compositions comprising an antimuscarinic and a long-acting beta-agonist
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
CN101969949B (zh) * 2008-03-14 2013-12-25 大塚制药株式会社 Mmp-2及/或mmp-9抑制剂
MX2010012492A (es) 2008-05-27 2010-12-21 Astrazeneca Ab Derivados de fenoxipiridinilamida y su uso en el tratamiento de estados de enfermedad mediados por fosfodiesterasa 4.
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
EP2156847A1 (en) * 2008-08-19 2010-02-24 Sanofi-Aventis New combination of active ingredients containing an alpha1-antagonist and a PDE 4 inhibitor.
DK2400950T3 (da) 2009-02-26 2019-07-29 Glaxo Group Ltd Farmaceutiske formuleringer omfattende 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
HUE044653T2 (hu) 2009-07-22 2019-11-28 PureTech Health LLC Készítmények olyan rendellenességek kezelésére, amelyek muszkarin-receptor aktiválással enyhíthetõk
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EA027692B1 (ru) 2010-08-03 2017-08-31 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Сухой порошковый препарат, содержащий ингибитор фосфодиэстеразы
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
RU2606121C2 (ru) 2011-06-10 2017-01-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Соединения, обладающие антагонистической активностью в отношении мускариновых рецепторов и агонистической активностью в отношении бета2-адренорецепторов
EP2718280B1 (en) 2011-06-10 2015-09-16 Chiesi Farmaceutici S.p.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
HRP20230147T1 (hr) * 2012-01-25 2023-03-31 Chiesi Farmaceutici S.P.A. Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom
JP6267685B2 (ja) 2012-04-13 2018-01-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 集合粒子
WO2014014698A2 (en) * 2012-07-16 2014-01-23 Barry University Inc. Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof
TW201427977A (zh) 2012-12-06 2014-07-16 Chiesi Farma Spa 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體致效劑活性之化合物
DK3345904T3 (da) 2012-12-06 2020-08-31 Chiesi Farm Spa Forbindelser med muskarinreceptorantagonist- og beta2-adrenerg receptoragonist-aktivitet
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
PT2968313T (pt) * 2013-03-15 2018-02-21 Verona Pharma Plc Combinação de fármacos
WO2015054101A1 (en) * 2013-10-09 2015-04-16 Icon Medical Corp. Improved metal alloy for medical devices
KR102250783B1 (ko) 2013-11-15 2021-05-11 퍼포먼스 폴리아미드 에스에이에스 금속 코팅용 폴리아미드 조성물 및 그것으로 코팅된 금속 성분
KR20160132372A (ko) * 2014-01-10 2016-11-18 디그너티 사이언스 리미티드 15-hepe를 포함하는 약제학적 조성물 및 이를 이용하는 천식 및 폐 장애의 치료 방법
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
AR104828A1 (es) 2015-06-01 2017-08-16 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
WO2017093208A1 (en) 2015-12-03 2017-06-08 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP3400214B1 (en) * 2016-01-08 2024-03-13 Theron Pharmaceuticals, Inc. Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives
WO2018011090A1 (en) 2016-07-13 2018-01-18 Chiesi Farmaceutici S.P.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP3625232B1 (en) 2017-05-19 2021-06-23 Council of Scientific and Industrial Research Substituted methanopyrido [2, 1-a]isoindolones as machr modulators for treating various associated pathophysiological conditions and process for preparation thereof
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
CA3180743A1 (en) 2018-09-28 2020-04-02 Karuna Therapeutics, Inc. Composition comprising xanomeline and trospium for treating disorders ameliorated by muscarinic receptor activation
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
IT202000006442A1 (it) * 2020-03-27 2021-09-27 Genetic S P A Budesonide 21-phosphate salts and pharmaceutical compositions containing the same
US11504332B2 (en) * 2021-03-23 2022-11-22 Vk Research Associates Inc. Phosphodiesterase-4 inhibitor combinations, methods of making, and methods of use thereof

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) * 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
FR2414044A1 (fr) * 1978-01-10 1979-08-03 Pharmindustrie Nouveaux derives d'aza-1 bicyclo(2,2,2) octane, utilisables comme medicaments
IT7920688V0 (it) 1979-02-05 1979-02-05 Chiesi Paolo Parma Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore.
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
FR2539135B1 (fr) * 1983-01-11 1986-02-28 Essilor Int Hydrogels de polyurethane et procede de fabrication
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
US4675326A (en) * 1985-05-08 1987-06-23 Gabriel Amitai Bisquaternary antidotes
US4843074A (en) * 1988-05-17 1989-06-27 Marion Laboratories, Inc. 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
US5290815A (en) * 1989-09-07 1994-03-01 Glaxo Group Limited Treatment of inflammation and allergy
US5610163A (en) * 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
US5507281A (en) * 1990-08-30 1996-04-16 Boehringer Ingelheim Kg Device for initiating a mechanical switching operation in synchronism with the breathing
DE4027391A1 (de) * 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
DE69132850T2 (de) 1990-09-26 2002-05-29 Pharmachemie Bv Wirbelkammer-Pulverinhalator
GB9026025D0 (en) * 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
US5290539A (en) * 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
DE4108393A1 (de) * 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
AU650953B2 (en) * 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
AU6048694A (en) * 1992-12-09 1994-07-04 Paul D. Jager Stabilized medicinal aerosol solution formulations
CZ287848B6 (en) 1992-12-18 2001-02-14 Schering Corp Inhalator of powder substances
GB9412434D0 (en) * 1994-06-21 1994-08-10 Inmos Ltd Computer instruction compression
WO1996032150A1 (en) 1995-04-14 1996-10-17 Glaxo Wellcome Inc. Metered dose inhaler for salmeterol
ATE209518T1 (de) 1995-06-21 2001-12-15 Asta Medica Ag Arzneipulverkartusche mit integrierter dosiereinrichtung, sowie pulverinhalator
DE19528145A1 (de) * 1995-08-01 1997-02-06 Boehringer Ingelheim Kg Neue Arzneimittel und ihre Verwendung
DE19536902A1 (de) * 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US6150415A (en) * 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
US5885834A (en) * 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
ITMI981671A1 (it) * 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
ES2193726T3 (es) * 1998-08-04 2003-11-01 Jago Res Ag Formulaciones de aerosol medicinales.
DE19847968A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US7214687B2 (en) * 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
US6410563B1 (en) * 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
FR2803378B1 (fr) * 1999-12-29 2004-03-19 Valeo Climatisation Echangeur de chaleur a tubes a plusieurs canaux, en particulier pour vehicule automobile
WO2001054728A1 (en) * 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha NOVEL REMEDIES WITH THE USE OF β3 AGONIST
ATE347557T1 (de) * 2000-03-23 2006-12-15 Takeda Pharmaceutical Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung
GB0008485D0 (en) * 2000-04-07 2000-05-24 Glaxo Group Ltd Pharmaceutical compositions
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009605D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
GB0009592D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
GB0009606D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
ME00220B (me) * 2000-05-22 2010-10-10 Chiesi Farm Spa Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
WO2002000241A2 (en) * 2000-06-28 2002-01-03 Aventis Pharma S.A. Compositions and methods for regulating the cell cycle using a ki gene or polypeptide
US6852728B2 (en) * 2000-10-14 2005-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them
US6706726B2 (en) * 2000-10-14 2004-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics which may be used as medicaments as well as processes for preparing them
US20020137764A1 (en) * 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US6608054B2 (en) * 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
US20020151541A1 (en) * 2000-10-31 2002-10-17 Michel Pairet Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
US20030158196A1 (en) * 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
US20020122773A1 (en) * 2000-12-20 2002-09-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and dopamine agonists
US6620438B2 (en) * 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
US20020193393A1 (en) * 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
CA2733294C (en) 2000-10-31 2011-12-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical combination of a tiotropium salt and ciclesonide
US20020183292A1 (en) * 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
US20020193392A1 (en) * 2000-11-13 2002-12-19 Christel Schmelzer Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
DE10056104A1 (de) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
AU2002238471B2 (en) * 2000-12-28 2007-06-28 Almirall, S.A. Quinuclidine derivatives and their use as M3 antagonists
US20020189610A1 (en) * 2001-02-01 2002-12-19 Karl-Heinz Bozung Pharmaceutical compositions containing an ipratropium salt and a betamimetic
US20020179087A1 (en) * 2001-02-01 2002-12-05 Karl-Heinz Bozung Pharmaceutical compositions containing an oxitropium salt and a betamimetic
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030216329A1 (en) * 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
AU2002314102A1 (en) * 2001-05-25 2002-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US6919325B2 (en) * 2001-09-14 2005-07-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts
US6974803B2 (en) * 2001-12-06 2005-12-13 Pfizer Inc Pharmaceutical combination
US6790856B2 (en) * 2002-01-31 2004-09-14 Boehringer Ingelheim Pharma Kg Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
US6756508B2 (en) * 2002-03-04 2004-06-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Cinnamic acid salts, processes for their preparation, and their use as medicaments
US7094788B2 (en) * 2002-04-13 2006-08-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Esters of hydroxyl-substituted nitrogen heterocycles, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions
ES2206021B1 (es) * 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
CN1668585A (zh) * 2002-07-08 2005-09-14 兰贝克赛实验室有限公司 用作蝇蕈碱受体拮抗剂的3,6－二取代氮杂双环[3.1.0]己烷衍生物
US20040058950A1 (en) * 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
WO2004039968A1 (ja) * 2002-10-30 2004-05-13 Japan Science And Technology Agency 骨髄由来の不死化樹状細胞株
ES2211315B1 (es) 2002-11-12 2005-10-16 Almirall Prodesfarma, S.A. Nuevos compuestos triciclicos.
AU2003289898A1 (en) * 2002-11-27 2004-06-18 Altana Pharma Ag Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
DE10307759B3 (de) * 2003-02-19 2004-11-18 Schering Ag Trimere makrocyclisch substituierte Benzolderivate, deren Herstellung und Verwendung als Kontrastmittel sowie diese enthaltende pharmazeutische Mittel
US20040184995A1 (en) * 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
US20060189642A1 (en) * 2003-03-28 2006-08-24 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
DE602004011494T2 (de) * 2003-03-28 2009-01-22 Nycomed Gmbh Synergistische kombination enthaltend roflumilast und einen anticholinergischen wirkstoff ausgewählt aus tiotropiumsalzen für die behandlung von atemwegserkrankungen
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20050026886A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
KR20060052911A (ko) * 2003-07-29 2006-05-19 베링거 인겔하임 인터내셔날 게엠베하 베타흥분제와 항콜린제를 포함하는 흡입용 의약품
CA2534120C (en) * 2003-07-31 2012-09-11 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising anticholinergics and a betamimetic
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
DE10347994A1 (de) * 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
EP1718336B1 (en) * 2004-02-06 2008-06-25 MEDA Pharma GmbH & Co. KG Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases
JP4700014B2 (ja) * 2004-02-06 2011-06-15 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト 呼吸器系疾患の治療用の抗コリン作用薬及び４型ホスホジエステラーゼの組合せ剤
EP1713473B1 (en) * 2004-02-06 2013-03-13 MEDA Pharma GmbH & Co. KG The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
US7375935B2 (en) * 2004-04-12 2008-05-20 Leviton Manufacturing Co., Inc. Ground fault circuit interrupter with enhanced radio frequency interference suppression
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
US20060189551A1 (en) * 2004-10-04 2006-08-24 Duke University Combination therapies for fungal pathogens

Also Published As

Publication number Publication date
ZA200609987B (en) 2007-12-27
ZA200609989B (en) 2007-11-28
IE20050366A1 (en) 2005-11-30
NO20065482L (no) 2006-12-22
BRPI0511662B8 (pt) 2021-05-25
NZ551667A (en) 2010-07-30
EP2292267A2 (en) 2011-03-09
NO20065483L (no) 2006-12-22
UA89182C2 (ru) 2010-01-11
EP2002845A2 (en) 2008-12-17
US20170049756A1 (en) 2017-02-23
US20160038470A1 (en) 2016-02-11
BRPI0511662A (pt) 2008-01-02
KR20070018105A (ko) 2007-02-13
KR101256417B1 (ko) 2013-04-22
UA89181C2 (ru) 2010-01-11
US20120071452A1 (en) 2012-03-22
NL1029151A1 (nl) 2005-12-05
DK1763368T4 (da) 2013-11-04
US20090093503A1 (en) 2009-04-09
NO20065477L (no) 2006-12-22
RU2404771C2 (ru) 2010-11-27
IL179689A (en) 2012-02-29
EP2292267B1 (en) 2014-07-23
JP2008500987A (ja) 2008-01-17
ECSP067036A (es) 2006-12-29
RS50787B2 (sr) 2018-02-28
US20120040943A1 (en) 2012-02-16
CN101018566A (zh) 2007-08-15
US20060189651A1 (en) 2006-08-24
US20130252928A1 (en) 2013-09-26
CA2568566C (en) 2012-12-18
CA2568566A1 (en) 2005-12-08
US20150202213A1 (en) 2015-07-23
EP1891973A1 (en) 2008-02-27
CY1108902T1 (el) 2014-07-02
ATE417627T1 (de) 2009-01-15
TWI404530B (zh) 2013-08-11
HK1090306A1 (en) 2006-12-22
ME01680B (me) 2010-08-31
ME02134B (me) 2015-02-27
US20050288266A1 (en) 2005-12-29
SI2292267T1 (sl) 2014-11-28
MXPA06004124A (es) 2006-06-27
BE1016608A5 (fr) 2007-02-06
US20140148420A1 (en) 2014-05-29
CL2011000607A1 (es) 2011-08-19
NO2015007I2 (no) 2015-12-21
CA2533061C (en) 2008-07-08
NO20065476L (no) 2006-12-28
JP2008500986A (ja) 2008-01-17
ES2348558T3 (es) 2010-12-09
CY1109938T1 (el) 2014-09-10
US20070232637A1 (en) 2007-10-04
EP2774622A1 (en) 2014-09-10
PE20060292A1 (es) 2006-04-14
SI21784A (sl) 2005-12-31
EP1763369A1 (en) 2007-03-21
CA2533061A1 (en) 2005-12-08
FR2870744A1 (fr) 2005-12-02
NO20065478L (no) 2006-12-28
CN1960759B (zh) 2011-07-13
JP2012184272A (ja) 2012-09-27
JP5049120B2 (ja) 2012-10-17
HUP0600139A2 (en) 2007-06-28
ECSP067038A (es) 2006-12-29
US20080051378A1 (en) 2008-02-28
NL300720I2 (es) 2016-01-07
NO2015007I1 (no) 2015-03-09
US20140296197A1 (en) 2014-10-02
JP5538485B2 (ja) 2014-07-02
MC200083A1 (fr) 2005-12-07
WO2005115467A1 (en) 2005-12-08
HUS1500011I1 (hu) 2018-09-28
JP2012012407A (ja) 2012-01-19
HRP20100489T1 (hr) 2010-10-31
JP2006527183A (ja) 2006-11-30
US20090111785A1 (en) 2009-04-30
US20100056486A1 (en) 2010-03-04
ITMI20051021A1 (it) 2005-12-01
WO2005115462A1 (en) 2005-12-08
ES2348680T3 (es) 2010-12-10
MXPA06013848A (es) 2007-03-01
EP2002845A3 (en) 2009-02-25
IL179687A (en) 2011-11-30
HRP20090107T3 (en) 2009-03-31
EP2002844A3 (en) 2009-03-04
ECSP067035A (es) 2006-12-29
ES2293849B2 (es) 2009-04-16
BRPI0511656A (pt) 2008-01-02
ZA200609986B (en) 2007-11-28
NZ551668A (en) 2010-06-25
RS50787B (sr) 2010-08-31
BRPI0511666A (pt) 2008-01-02
EP1763369B1 (en) 2008-12-17
IL179687A0 (en) 2007-05-15
DK2292267T3 (da) 2014-09-15
UA89183C2 (ru) 2010-01-11
BRPI0511669A (pt) 2008-01-02
US20110021478A1 (en) 2011-01-27
EP2292267A3 (en) 2011-06-15
HRP20090215T4 (hr) 2013-12-20
PT1763369E (pt) 2009-02-26
EP1765404A1 (en) 2007-03-28
ES2257152B1 (es) 2007-07-01
US20080146603A1 (en) 2008-06-19
SI1763369T1 (sl) 2009-06-30
GB2419819B (en) 2007-02-21
CA2569077A1 (en) 2005-12-08
AR049066A1 (es) 2006-06-21
JP2008500989A (ja) 2008-01-17
PT1891973E (pt) 2010-09-27
PL379660A1 (pl) 2006-11-13
EP2210613A1 (en) 2010-07-28
US20120059031A1 (en) 2012-03-08
US20150306079A1 (en) 2015-10-29
NL1029151C2 (nl) 2006-06-22
US20130310354A1 (en) 2013-11-21
CY1115669T1 (el) 2017-01-25
JP5133054B2 (ja) 2013-01-30
AU2005247103A1 (en) 2005-12-08
EP2319538A2 (en) 2011-05-11
NL300720I1 (es) 2016-01-07
JP5107701B2 (ja) 2012-12-26
NO334337B1 (no) 2014-02-10
UA86976C2 (ru) 2009-06-10
EP1763368B1 (en) 2009-03-11
MXPA06013847A (es) 2007-03-01
US20150080359A1 (en) 2015-03-19
EP2002843A3 (en) 2009-04-08
NO20065479L (no) 2006-12-22
AU2005247108A1 (en) 2005-12-08
CH696962A5 (fr) 2008-02-29
EP1763368A1 (en) 2007-03-21
PT2292267E (pt) 2014-10-15
CN102085373A (zh) 2011-06-08
PL2292267T3 (pl) 2015-03-31
US20070167489A1 (en) 2007-07-19
ZA200609985B (en) 2008-09-25
RU2404771C3 (ru) 2018-03-12
DK1763368T3 (da) 2009-05-04
NZ544539A (en) 2007-09-28
ES2293849A1 (es) 2008-03-16
US20120302532A1 (en) 2012-11-29
CA2569077C (en) 2012-12-18
ECSP067034A (es) 2006-12-29
ECSP067033A (es) 2006-12-29
JP4928258B2 (ja) 2012-05-09
PE20081650A1 (es) 2008-12-06
RU2010129940A (ru) 2012-01-27
US20100048615A1 (en) 2010-02-25
DE602005013220D1 (de) 2009-04-23
LTC1763368I2 (lt) 2016-12-27
US20200009117A1 (en) 2020-01-09
US20080045565A1 (en) 2008-02-21
PL1891973T3 (pl) 2010-11-30
DK1763369T3 (da) 2009-03-16
WO2005115466A8 (en) 2007-01-04
MY142095A (en) 2010-09-15
DK1765404T3 (da) 2009-03-16
US20130035319A1 (en) 2013-02-07
ES2318498T3 (es) 2009-05-01
RS53529B1 (en) 2015-02-27
EP2319538A3 (en) 2011-06-15
ZA200609990B (en) 2007-12-27
BRPI0511662B1 (pt) 2019-02-19
DE602005011803D1 (de) 2009-01-29
SI1763368T2 (sl) 2013-12-31
HRP20140864T1 (hr) 2014-12-05
CN102755321B (zh) 2015-07-15
AU2005247107A1 (en) 2005-12-08
AU2005247108B2 (en) 2008-09-11
CY2015006I1 (el) 2016-06-22
CY1110798T1 (el) 2015-06-10
KR20130027586A (ko) 2013-03-15
SI1891973T1 (sl) 2010-11-30
EP2002844B1 (en) 2010-12-29
US20120309726A1 (en) 2012-12-06
JP2008500990A (ja) 2008-01-17
US20140094442A1 (en) 2014-04-03
US20180200234A1 (en) 2018-07-19
FR2870744B1 (fr) 2006-12-08
IL179684A0 (en) 2007-05-15
CN1960761A (zh) 2007-05-09
US20120088743A1 (en) 2012-04-12
CY2015006I2 (el) 2016-06-22
US20060154934A1 (en) 2006-07-13
BRPI0511667A (pt) 2008-01-02
UA89184C2 (ru) 2010-01-11
US20120309727A1 (en) 2012-12-06
TW200608971A (en) 2006-03-16
RU2006142331A (ru) 2008-06-20
EP2138188A1 (en) 2009-12-30
JP2008500988A (ja) 2008-01-17
ME01670B (me) 2010-06-30
LU91214B1 (fr) 2006-01-26
RS50717B (sr) 2010-06-30
KR101174677B1 (ko) 2012-08-17
RU2373935C2 (ru) 2009-11-27
HK1125573A1 (en) 2009-08-14
KR20070024556A (ko) 2007-03-02
CN1960759A (zh) 2007-05-09
EP2002844A2 (en) 2008-12-17
ES2505329T3 (es) 2014-10-09
ZA200600261B (en) 2007-04-25
PE20081649A1 (es) 2008-11-28
HK1095757A1 (en) 2007-05-18
EP1761280A1 (en) 2007-03-14
ES2257152A1 (es) 2006-07-16
GR1006045B (el) 2008-09-08
RU2385721C2 (ru) 2010-04-10
EP2002843A2 (en) 2008-12-17
CN102755321A (zh) 2012-10-31
US20110021476A1 (en) 2011-01-27
JP5032984B2 (ja) 2012-09-26
GR20050100269A (el) 2005-12-31
ES2322280T5 (es) 2013-12-03
US20050267078A1 (en) 2005-12-01
GB2419819A (en) 2006-05-10
GB0526502D0 (en) 2006-02-08
ECSP067037A (es) 2006-12-29
CN1960762A (zh) 2007-05-09
ME02779B (me) 2010-06-30
CY1109139T1 (el) 2014-07-02
PT1763368E (pt) 2009-05-14
PL1763368T3 (pl) 2009-08-31
IL179684A (en) 2011-11-30
US20050267135A1 (en) 2005-12-01
WO2005115466A1 (en) 2005-12-08
PL1763368T5 (pl) 2014-01-31
HRP20090215T1 (en) 2009-05-31
AU2005247103B2 (en) 2010-10-28
US20090176751A1 (en) 2009-07-09
ES2322280T3 (es) 2009-06-18
ATE424847T1 (de) 2009-03-15
CY1108885T1 (el) 2014-07-02
HK1198120A1 (en) 2015-03-13
IL179689A0 (en) 2007-05-15
US20110021477A1 (en) 2011-01-27
NO338621B1 (no) 2016-09-19
EP2774622B1 (en) 2015-03-11
EP2774623B1 (en) 2015-04-08
RU2006147250A (ru) 2008-07-20
PL1763369T3 (pl) 2009-06-30
SI1763368T1 (sl) 2009-08-31
CN1972716A (zh) 2007-05-30
US20090099148A1 (en) 2009-04-16
CN1960760A (zh) 2007-05-09
RS51386B (en) 2011-02-28
US20060205702A1 (en) 2006-09-14
UA89185C2 (ru) 2010-01-11
AU2005247107B2 (en) 2010-10-28
BRPI0511660A (pt) 2008-01-02
ATE474600T1 (de) 2010-08-15
RU2006147268A (ru) 2008-07-20
EP1763368B2 (en) 2013-08-21
US20100048616A1 (en) 2010-02-25
EP1891973B1 (en) 2010-07-21
EP2774623A1 (en) 2014-09-10
DK1891973T3 (da) 2010-10-18
EP1765404B1 (en) 2008-12-31
HUP0600139A3 (en) 2010-12-28
JP4966192B2 (ja) 2012-07-04
PL1765404T3 (pl) 2009-06-30
DE602005022497D1 (de) 2010-09-02
RU2465902C2 (ru) 2012-11-10

Similar Documents

Publication Publication Date Title
UY28933A1 (es) Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos
BRPI0511396A (pt) derivados de retinal e métodos para uso no tratamento de enfermidades visuais
CL2007002635A1 (es) Compuestos derivados de quinazolinona e isoquinolinona, moduladores de la actividad del eje hpa; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion relacionado con estres o depresion.
ECSP10010007A (es) Tratamiento con ligandos alpha-7-selectivos
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
AR059390A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
BRPI0717845A2 (pt) Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
HN2008001720A (es) Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
ECSP067093A (es) Derivados de sulfamato y sulfamida para el tratamiento de epilepsia y trastornos relacionados
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
BRPI0514474A (pt) multiparticulados
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
SV2010003559A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
MX2009013332A (es) Inhibidores de ire-1 alfa.
AR052774A1 (es) Inmunoterapia para trastornos autoinmunes
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
CL2007001318A1 (es) Uso de flibanserina,opcionalmente como base libre,sal hidrato o solvato de ella,para preparar un medicamento util en el tratamiento de trastornos de deseo sexual en mujeres.
BRPI0814529A2 (pt) Derivados de 2-3-dihidrobenzo[1,4]dioxin-2-ilmetil como antagonistas alfa2c para o uso no tratamento de doenças do sistema nervoso periférico e central.
ES2570332T3 (es) La combinación de anticolinérgicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
CL2008003057A1 (es) Combinacion farmaceutica que comprende un derivado de purina y un corticoide, agonista de beta-2 adrenoceptor, agente antimuscarinico, entre otros; composicion farmaceutica; y su uso para tratar enfermedades inflamatorias u obstructivas de las vias respiratorias.
UY29417A1 (es) Agentes endoparasiticidas
CO6551744A2 (es) Combinación de fármacos con teobromina y su uso en terapia

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170516